3 years ago

Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors

Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides
as ROMK Inhibitors
Kevin J. Filipski, Aaron C. Smith, Markus Boehm, Brett M. Antonio, Dilinie P. Fernando, Anthony Carlo, James R. Gosset, Andre Shavnya, Neil A. Castle, Jerod S. Denton, Matthew S. Dowling, Matthew F. Sammons, Sujay V. Kharade, Shannon G. Zellmer, Philip A. Carpino
Inhibitors of the renal outer medullary potassium channel (ROMK) show promise as novel mechanism diuretics, with potentially lower risk of diuretic-induced hypokalemia relative to current thiazide and loop diuretics. Here, we report the identification of a novel series of 3-sulfamoylbenzamide ROMK inhibitors. Starting from HTS hit 4, this series was optimized to provide ROMK inhibitors with good in vitro potencies and well-balanced ADME profiles. In contrast to previously reported small-molecule ROMK inhibitors, members of this series were demonstrated to be highly selective for inhibition of human over rat ROMK and to be insensitive to the N171D pore mutation that abolishes inhibitory activity of previously reported ROMK inhibitors.

Publisher URL: http://dx.doi.org/10.1021/acsmedchemlett.7b00481

DOI: 10.1021/acsmedchemlett.7b00481

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.